Vera Therapeutics (Nasdaq:VERA) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

VERA 주식 개요

임상 단계의 생명공학 회사인 베라 테라퓨틱스는 심각한 면역 질환 환자를 위한 치료법을 개발하고 상용화하는 데 주력하고 있습니다.

VERA 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	5/6
배당금	0/6

보상

공정 가치 추정치보다 낮은 89.3% 에서 거래

위험 분석

수익이 1백만 달러 미만인 경우 ( $0 )

현재 수익성이 없으며 향후 3년 동안 수익을 낼 것으로 예상되지 않습니다.

지난 1년 동안 주주가 희석되었습니다.

지난 3개월간 상당한 내부자 매도

Vera Therapeutics, Inc. 경쟁사

Kymera Therapeutics

NasdaqGM:KYMR

US$1.9b

Protagonist Therapeutics

NasdaqGM:PTGX

US$1.9b

Rocket Pharmaceuticals

NasdaqGM:RCKT

US$2.2b

Zai Lab

NasdaqGM:ZLAB

US$1.9b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Vera Therapeutics
과거 주가
현재 주가	US$35.23
52주 최고치	US$50.78
52주 최저치	US$9.24
베타	1.04
11개월 변경	-5.07%
3개월 변경 사항	-19.62%
1년 변경 사항	100.86%
33년 변화	157.15%
5년 변화	n/a
IPO 이후 변화	206.35%

최근 뉴스 및 업데이트

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

주주 수익률

	VERA	US Biotechs	US 마켓
7D	-0.8%	2.0%	-0.3%
1Y	100.9%	12.4%	22.3%

수익률 대 산업: VERA 지난 1년 동안 6.7 %를 반환한 US Biotechs 산업을 초과했습니다.

수익률 대 시장: VERA 지난 1년 동안 23.3 %를 반환한 US 시장을 초과했습니다.

가격 변동성

Is VERA's price volatile compared to industry and market?
VERA volatility
VERA Average Weekly Movement	9.2%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.9%

안정적인 주가: VERA 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: VERA 의 주간 변동성( 9% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2016	55	Marshall Fordyce	veratx.com

베라 테라퓨틱스는 임상 단계의 생명공학 회사로 중증 면역 질환 환자를 위한 치료제를 개발하고 상용화하는 데 주력하고 있습니다. 주요 제품 후보로는 피하 주사제로 자가 투여하는 융합 단백질인 아타시셉트가 있으며, 면역글로불린 A 신장병 환자를 대상으로 임상 3상 시험 중이고, 루푸스 신염 치료제로는 임상 2상 시험 중입니다. 또한 BK 바이러스 감염 치료를 위한 인간 단일 클론 항체 MAU868도 개발 중입니다.

Vera Therapeutics, Inc. 기본 사항 요약

Vera Therapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
VERA 기본 통계
시가총액	US$1.91b
수익(TTM)	-US$94.30m
수익(TTM)	n/a

0.0x

P/S 비율

-20.4x

P/E 비율

VERA 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
VERA 손익 계산서(TTM)
수익	US$0
수익 비용	US$0
총 이익	US$0
기타 비용	US$94.30m
수익	-US$94.30m

최근 보고된 수익

Mar 31, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	-1.72
총 마진	0.00%
순이익 마진	0.00%
부채/자본 비율	14.2%

VERA 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

VERA 주식 개요

보상

위험 분석

Vera Therapeutics, Inc. 경쟁사

NasdaqGM:KYMR

US$1.9b

NasdaqGM:PTGX

US$1.9b

NasdaqGM:RCKT

US$2.2b

NasdaqGM:ZLAB

US$1.9b

가격 내역 및 성능

최근 뉴스 및 업데이트

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Recent updates

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Independent Chairman of the Board recently bought US$215k worth of stock